Developed to compare mixture chemotherapy (epirubicin/oxaliplatin/capecitabine, EOX regimen) with
Chemexpress Developed to examine combination chemotherapy (epirubicin/oxaliplatin/capecitabine, EOX regimen) with or without panitumumab in 553 patients with advanced esophagogastric adenocarcinoma at 63 centers. Median OS in 275 patients allocated to EOX…